ea0081ep673 | Pituitary and Neuroendocrinology | ECE2022
M. Weber Matthias
, B. Gordon Murray
, Hoybye Charlotte
, H. Olsen Anne
, Kelepouris Nicky
, Nedjatian Navid
, M.K. Biller Beverly
Introduction: There are limited data on the effectiveness and safety of GHRT in older patients with AGHD. We compared real-world GHRT outcomes in older (aged ≥60 years) vs middle-aged (35<60 years) adults.Methods: NordiNet® IOS (NCT00960128) and ANSWER (NCT01009905) were non-interventional studies investigating long-term effectiveness and safety of GHRT with Norditropin® (somatropin, Novo Nordisk). Safety was assessed in the ful...